Skip to content

Observation on the Bronchodilatory Effect of Esketamine in Painless Fiberoptic Bronchoscopy

Observation on the Bronchodilatory Effect of Esketamine in Painless Fiberoptic Bronchoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109556
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-09-30
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease of respiratory system

Interventions

Sponsors

Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing painless fiberoptic bronchoscopy at the Affiliated Hospital of Guizhou Medical University from January 2024 to December 2024; 2. Aged 18 to 75 years (including the cutoff values); 3. ASA classification I to III; 4. 18 kg/m^2 < BMI < 30 kg/m^2; 5. Patients with complete anesthesia records and fiberoptic bronchoscopy reports.

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to general anesthesia, or have a history of anesthetic complications; 2. Those with a history of hyperthyroidism; 3. Those with mental system disorders (such as schizophrenia, mania, delirium, etc.) or cognitive dysfunction; 4. Long-term (continuous or intermittent) use of benzodiazepine sleeping pills, opioid analgesics, or use of anesthetic analgesics within the random 24 hours prior or anesthetics within 7 days; 5. Severe anemia or coagulopathy; 6. Pregnant or breastfeeding women; 7. Those with severely difficult airways (with a modified Mallampati score of IV); 8. Those with a history of drug abuse or alcoholism within the last 2 years before screening; 9. Those who are allergic or have contraindications to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
The incidence of tracheal spasm;

Secondary

MeasureTime frame
Demographic data;Change in the diameter of the trachea;The lowest value of blood oxygen saturation (SpO2) and the duration of time with SpO2 less than 90%;The fluctuation range of heart rate (HR) and blood pressure (BP);The incidence rate of adverse reactions recorded;Wake-up time;

Countries

China

Contacts

Public ContactJiang Ke

Affiliated Hospital of Guizhou Medical University

348697044@qq.com+86 180 9600 1863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026